Libtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer

Recommendation based on a Phase 3 Libtayo trial that was first and only to demonstrate significantly improved survival compared to chemotherapy in...

Related Keywords

Australia ,Taiwan ,Japan ,United Kingdom ,Belgium ,Brazil ,Italy ,Canada ,Russia ,Poland ,South Korea ,Spain ,Greece ,Georged Yancopoulos ,Regeneron Velocimmune ,Regeneron Pharmaceuticals ,Prnewswire Regeneron Pharmaceuticals Inc ,Regeneron Pharmaceuticals Inc ,Twitter ,Regeneron Genetics Center ,European Commission ,Data Monitoring Committee ,Regeneron Velocimmune Technology ,European Commission Of Libtayo ,Nasdaq ,Exchange Commission ,European Union ,European Medicines Agency ,Committee For Medicinal Products Human Use ,Medicinal Products ,Human Use ,New England Journal ,Independent Data Monitoring ,Nonproprietary Naming ,Biological Products Guidance ,Chief Scientific Officer George ,Prescribing Information ,Regeneron Genetics ,Forward Looking Statements ,Product Candidates ,Media Relations Taylor Ramsey Tel ,Relations Vesna Tosic Tel ,